 "AstraZeneca’s Covid-19 vaccine shows less effect against S Africa variant")
AstraZeneca’s Covid-19 vaccine has shown limited efficacy against mild disease caused by the variant first identified in South Africa, according to early data in a small phase trial.
Efficacy against severe Covid-19 cases, hospitalisation and deaths hasn’t yet been determined, “given that subjects were predominantly young healthy adults,” a spokesperson for AstraZeneca said in a statement.
None of the participants in the study died or was hospitalised, according to the Financial Times, which first reported on the findings. The study, with a relatively small sample size of more than 2,000 individuals, hasn’t yet been peer-reviewed and is due
Efficacy against severe Covid-19 cases, hospitalisation and deaths hasn’t yet been determined, “given that subjects were predominantly young healthy adults,” a spokesperson for AstraZeneca said in a statement.
None of the participants in the study died or was hospitalised, according to the Financial Times, which first reported on the findings. The study, with a relatively small sample size of more than 2,000 individuals, hasn’t yet been peer-reviewed and is due
